The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
CORRECTION: Veeva Sys Q3 Adj $1.34 Beats $1.30 Estimate, Sales $616.50M Beat $615.82M Estimate
Veeva Sys (NYSE:VEEV) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.30 by 3.08…
C3.ai Q2 Earnings Highlights: Revenue Miss, EPS Beat, ‘Unprecedented Interest And Traction’ In Generative AI Offerings
C3.Ai Inc (NYSE:AI) reported fiscal second-quarter financial results Wednesday after the bell. Here’s a look at the key metrics from the…
Shhh….Tomorrow’s Market Secrets – Delivered Today
Market Briefing As we begin a critical stretch in the second full week of May, traders are navigating a landscape…